AU Patent

AU2016363005A1 — Cerdulatinib for treating hematological cancers

Assigned to Portola Pharmaceuticals LLC · Expires 2018-07-05 · 8y expired

What this patent protects

Disclosed herein are methods and uses of cerdulatinib for treating diseases or conditions, including hematological cancers, and combinations of cerdulatinib for treating such diseases or conditions.

USPTO Abstract

Disclosed herein are methods and uses of cerdulatinib for treating diseases or conditions, including hematological cancers, and combinations of cerdulatinib for treating such diseases or conditions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016363005A1
Jurisdiction
AU
Classification
—
Expires
2018-07-05
Drug substance claim
No
Drug product claim
No
Assignee
Portola Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.